HURANasdaqPharmaceutical PreparationsFiscal year ends December 31

TuHURA Biosciences, Inc./NV

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.78+0.02 (+1.14%)

Close on Oct 19, 2026

Market cap: $113.86M
P/E (TTM): –
Dividend yield: –

TuHURA Biosciences, Inc./NV cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2016 2016-06-30	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Depreciation & Amortization	0.07	–	–	–	–	–	–	–	–	–	–	–
Stock-Based Compensation	6.42	1.49	2.25	5.28	0.50	0.43	0.50	0.12	0.39	2.15	1.13	0.10
Deferred Income Taxes	0	–	–	–	–	–	–	–	–	–	–	–
Change in Accounts Payable	-3.76	-0.44	1.01	-0.07	0.21	0.20	0.30	0.60	-0.18	-0.54	0.87	0.10
Operating Cash Flow	-28	-12	-20	-19	-7.93	-6.33	-9.85	-8.02	-5.15	-5.52	-0.58	-0.23
Capital Expenditures	-0.08	–	-0.18	–	–	–	–	–	–	–	–	–
Acquisitions	–	–	-0.30	-0.30	–	–	–	–	–	–	–	–
Sale & Maturity of Investments	–	–	–	–	–	–	–	–	–	8.58	–	–
Investing Cash Flow	-1.34	-0.23	–	0.96	–	–	-0.01	-0.02	-0.02	–	–	–
Stock Issued	18	–	–	–	–	–	–	–	–	–	–	0.03
Debt Repaid	–	–	–	-0.50	–	–	–	–	–	–	–	–
Financing Cash Flow	20	1.85	22	26	6.60	4.07	9.25	8.47	9.57	9.64	0.58	0.22
Net Change in Cash	-9.04	-10	1.24	8.15	-1.33	-2.25	-0.61	0.43	4.40	4.12	0.00	-0.01
Free Cash Flow	-28	–	-21	–	–	–	–	–	–	–	–	–
Income Taxes Paid	0	–	–	–	–	–	–	–	–	–	–	–
Interest Paid	0.06	–	–	0.03	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -277.4%

Financial strength

Current ratio: 0.18
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 10.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 6.15
Dividend yield: –